Last reviewed · How we verify
Drug: gemcitabine, S-1
Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha
Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha Used for Pancreatic cancer, Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | Drug: gemcitabine, S-1 |
|---|---|
| Also known as | gemzer, TS-1 |
| Sponsor | Osaka Medical Center for Cancer and Cardiovascular Diseases |
| Drug class | Nucleoside analog |
| Target | Ribonucleotide reductase, DNA polymerase alpha |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine is a nucleoside analog that is metabolized into its active forms, which are then incorporated into DNA, causing chain termination during DNA replication. S-1 is a combination of tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (a cytosine deaminase inhibitor), which enhances the antitumor activity of 5-fluorouracil while reducing its gastrointestinal toxicity.
Approved indications
- Pancreatic cancer
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Mucositis
- Stomatitis
- Alopecia
Key clinical trials
- Metastasis-directed Therapy for Oligometastases of Breast Cancer (PHASE3)
- Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients (PHASE1, PHASE2)
- Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (PHASE3)
- Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer (PHASE3)
- SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer (PHASE2)
- Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (PHASE2)
- Personalized Precision Diagnosis and Treatment of Pancreatic Cancer (NA)
- RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: